NASDAQ:AVXL Anavex Life Sciences (AVXL) Stock Price, News & Analysis $5.15 -0.41 (-7.37%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$5.09▼$5.6050-Day Range$4.11▼$7.0452-Week Range$3.25▼$10.45Volume865,967 shsAverage Volume1.25 million shsMarket Capitalization$435.91 millionP/E RatioN/ADividend YieldN/APrice Target$40.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Anavex Life Sciences alerts: Email Address Anavex Life Sciences MarketRank™ Stock AnalysisAnalyst RatingStrong Buy3.50 Rating ScoreUpside/Downside676.7% Upside$40.00 Price TargetShort InterestBearish23.33% of Shares Sold ShortDividend StrengthN/ASustainability-0.83Upright™ Environmental ScoreNews SentimentN/AInsider TradingAcquiring Shares$10,319 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.55) to ($0.80) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.60 out of 5 starsMedical Sector231st out of 910 stocksBiological Products, Except Diagnostic Industry32nd out of 155 stocks 3.8 Analyst's Opinion Consensus RatingAnavex Life Sciences has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAnavex Life Sciences has only been the subject of 2 research reports in the past 90 days.Read more about Anavex Life Sciences' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted23.33% of the outstanding shares of Anavex Life Sciences have been sold short.Short Interest Ratio / Days to CoverAnavex Life Sciences has a short interest ratio ("days to cover") of 17.2, which indicates bearish sentiment.Change versus previous monthShort interest in Anavex Life Sciences has recently decreased by 0.65%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAnavex Life Sciences does not currently pay a dividend.Dividend GrowthAnavex Life Sciences does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAnavex Life Sciences has received a 73.63% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Clinical research services for genetic diseases", "Preclinical research services for mental health", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Anavex Life Sciences is -0.83. Previous Next 1.3 News and Social Media Coverage News SentimentAnavex Life Sciences has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Anavex Life Sciences this week, compared to 3 articles on an average week.Search InterestOnly 6 people have searched for AVXL on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Anavex Life Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -74% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Anavex Life Sciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $10,319.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders11.00% of the stock of Anavex Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 31.55% of the stock of Anavex Life Sciences is held by institutions.Read more about Anavex Life Sciences' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Anavex Life Sciences are expected to decrease in the coming year, from ($0.55) to ($0.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Anavex Life Sciences is -10.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Anavex Life Sciences is -10.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnavex Life Sciences has a P/B Ratio of 3.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Anavex Life Sciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Golden CrestBiden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.>> Get Your FREE Wealth Protection Guide << About Anavex Life Sciences Stock (NASDAQ:AVXL)Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.Read More AVXL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AVXL Stock News HeadlinesSeptember 3, 2024 | globenewswire.comAnavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024August 7, 2024 | markets.businessinsider.comBuy Rating on Anavex Life Sciences Amid Anticipated European Approval and Market Opportunity for Alzheimer’s Drug BlarcamesineSeptember 7, 2024 | Weiss Ratings (Ad)“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.August 7, 2024 | finanznachrichten.deAnavex Life Sciences Corp.: Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business UpdateAugust 7, 2024 | finance.yahoo.comAnavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business UpdateAugust 7, 2024 | markets.businessinsider.comBuy Rating on Anavex Life Sciences: Upcoming Catalysts and Positive Trial Outcomes Fuel OptimismAugust 7, 2024 | seekingalpha.comAnavex Life Sciences Corp. (AVXL) Q2 2024 Earnings Call TranscriptAugust 6, 2024 | globenewswire.comAnavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business UpdateSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 1, 2024 | globenewswire.comAnavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024July 31, 2024 | markets.businessinsider.comBuy Rating Affirmed for Anavex Life Sciences on Blarcamesine’s Promising Alzheimer’s Treatment PotentialJuly 30, 2024 | seekingalpha.comAnavex: An Update To Their Phase 2b/3 Alzheimer's Trial DataJuly 30, 2024 | globenewswire.comAnavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X ConferenceJuly 29, 2024 | seekingalpha.comAnavex Life Sciences: Short-Lived Spike On Latest Alzheimer's Data Not SurprisingJuly 29, 2024 | marketwatch.comAnavex Life Sciences Shares Rise on Positive Results of Alzheimer's Clinical TrialJuly 29, 2024 | finance.yahoo.comNeurodegenerative Disease-Focused Anavex Life Sciences' Alzheimer's Candidate Slows Disease Progression By Almost 39%July 28, 2024 | globenewswire.comResults from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association ConferenceJuly 23, 2024 | msn.comEF Hutton Initiates Coverage of Anavex Life Sciences (AVXL) with Buy RecommendationSee More Headlines Receive AVXL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anavex Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today9/07/2024Fiscal Year End9/30/2024Next Earnings (Estimated)11/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AVXL CUSIPN/A CIK1314052 Webwww.anavex.com Phone(844) 689-3939FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$40.00 High Stock Price Target$40.00 Low Stock Price Target$40.00 Potential Upside/Downside+676.7%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,510,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-30.64% Return on Assets-28.23% Debt Debt-to-Equity RatioN/A Current Ratio12.04 Quick Ratio12.04 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.53 per share Price / Book3.37Miscellaneous Outstanding Shares84,642,000Free Float75,331,000Market Cap$435.91 million OptionableOptionable Beta0.63 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Christopher U. Missling M.B.A. (Age 58)M.S., Ph.D., President, CEO, Secretary & Director Comp: $828.25kMs. Sandra Boenisch CPA (Age 43)CGA, Principal Financial Officer & Treasurer Comp: $194.36kMr. Stephan Toutain M.B.A. (Age 58)M.S., Senior VP of Operations & COO Dr. Walter E. Kaufmann M.D.Chief Scientific OfficerClint TomlinsonVP of CorporateDr. Adebayo Laniyonu Ph.D.Senior Vice President of Nonclinical DevelopmentDr. Edward R Hammond M.D.M.P.H., Ph.D., Chief Medical OfficerDr. Kun Jin Ph.D.Head of BiostatisticsMr. David Goldberger R.Ph.Senior Vice President of Regulatory AffairsMore ExecutivesKey CompetitorsBioanalytical SystemsNASDAQ:BASIAkero TherapeuticsNASDAQ:AKROImmunocoreNASDAQ:IMCRKeros TherapeuticsNASDAQ:KROSArvinasNASDAQ:ARVNView All CompetitorsInsiders & InstitutionsDeerfield Management Company L.P. Series CBought 81,890 shares on 8/15/2024Ownership: 0.097%AQR Capital Management LLCBought 26,821 shares on 8/15/2024Ownership: 0.053%The Manufacturers Life Insurance Company Bought 2,401 shares on 8/15/2024Ownership: 0.036%Marshall Wace LLPBought 39,351 shares on 8/14/2024Ownership: 0.046%ProShare Advisors LLCSold 3,837 shares on 8/14/2024Ownership: 0.018%View All Insider TransactionsView All Institutional Transactions AVXL Stock Analysis - Frequently Asked Questions How have AVXL shares performed this year? Anavex Life Sciences' stock was trading at $9.31 on January 1st, 2024. Since then, AVXL stock has decreased by 44.7% and is now trading at $5.15. View the best growth stocks for 2024 here. How were Anavex Life Sciences' earnings last quarter? Anavex Life Sciences Corp. (NASDAQ:AVXL) posted its quarterly earnings results on Tuesday, August, 6th. The biotechnology company reported ($0.14) EPS for the quarter, topping analysts' consensus estimates of ($0.15) by $0.01. Who are Anavex Life Sciences' major shareholders? Anavex Life Sciences' top institutional investors include Renaissance Technologies LLC (0.55%), Sculptor Capital LP, Bank of New York Mellon Corp (0.33%) and Rhumbline Advisers (0.14%). Insiders that own company stock include Athanasios Skarpelos, Christopher U Missling, Steffen Thomas and Peter DO Donhauser. View institutional ownership trends. How do I buy shares of Anavex Life Sciences? Shares of AVXL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Anavex Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Anavex Life Sciences investors own include Inovio Pharmaceuticals (INO), POET Technologies (POETF), Brainstorm Cell Therapeutics (BCLI), LadRx (CYTR), SharkNinja (SN), Novavax (NVAX) and Geron (GERN). This page (NASDAQ:AVXL) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anavex Life Sciences Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anavex Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AVXL Stock Alerts